重新审视突变预防浓度以指导儿童结核病给药
本文讨论突变预防浓度(MPC)在儿童结核病治疗中的应用。文章指出,基因组学和定量药敏检测显示结核分枝杆菌的MIC范围较广,常由特定突变和菌株类型决定;儿童药代动力学研究提示,即使提高剂量推荐,部分儿童仍未达到成人来源的目标浓度。作者建议将MPC纳入儿童药代动力学研究,以更准确确定适宜浓度目标,限制耐药突变株生长。
要点
- 儿童结核即使提高剂量,部分患儿仍未达成人来源的药代动力学目标浓度
- 基因组学与定量药敏显示结核菌MIC范围广,常由特定突变和菌株类型决定
- 建议将MPC纳入儿童药代动力学研究,以优化剂量并限制耐药突变株生长
核心结论
- 建议在儿童抗结核药物剂量研究中考虑MPC,并将其纳入药代动力学研究,以更准确确定儿童适宜浓度目标,限制耐药突变株生长并更好管理耐药结核。
研究设计与样本
- 本文为J Antimicrob Chemother发表的综述性文章,讨论MPC概念在儿童结核病给药中的应用,未报告系统检索范围。
主要发现
- 早期研究显示单突变可导致对一线和二线抗结核药物的MIC升高。
- 基因组学和定量药敏检测的广泛应用提示结核菌MIC范围较广,常由特定突变和菌株类型决定。
- 儿童药代动力学研究提示,尽管剂量推荐不断提高,部分儿童仍未达到成人来源的目标浓度。
临床怎么用
- 在儿童抗结核给药和新型治疗引入时,可考虑将MPC作为药代动力学研究的浓度目标参考,以限制耐药突变株生长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The mutant prevention concentration (MPC) is a well-known concept in the chemotherapy of many bacterial infections, but is seldom considered in relation to tuberculosis (TB) treatment, as the required concentrations are generally viewed as unachievable without undue toxicity. Early studies revealed single mutations conferring high MICs of first- and second-line anti-TB agents; however, the growing application of genomics and quantitative drug susceptibility testing in TB suggests a wide range of MICs often determined by specific mutations and strain type. In paediatric TB, pharmacokinetic studies indicate that despite increasing dose recommendations, a proportion of children still do not achieve adult-derived targets. When considering the next stage in anti-TB drug dosing and the introduction of novel therapies for children, we suggest consideration of MPC and its incorporation into pharmacokinetic studies to more accurately determine appropriate concentration targets in children, to restrict the growth of resistant mutants and better manage drug-resistant TB.
引用
- Jaganath D, Schaaf HS, Donald PR, et al. Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis. J Antimicrob Chemother. 2017. PMID: 28333284. doi:10.1093/jac/dkx051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。